ClinicalTrials.gg
CompletedNCT00029848RIO-DiabetesUpdated Apr 20, 2009

Obese Patients With Type 2 Diabetes

A Phase 3 interventional study of Rimonabant (SR141716) in Obesity, Diabetes Mellitus, Non-Insulin-Dependent and Obesity in Diabetes, sponsored by Sanofi. Completed at 55 sites in 11 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2009-04-20.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,045
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing rimonabant in Obesity — none open to participants now, none under way, none of them phase 3. Rimonabant · Obesity.

Enrollment
5th of 21
1,045 · median 643
Started
2001
with 3 others
Phase 3
18 of 21
none open now
Registered
1st of 21
by date
Lead sponsor
19 of 21
Sanofi

Among the 21 studies testing rimonabant in Obesity, this one is the 5th largest by enrollment, is one of 4 that started in 2001, is one of 18 in phase 3, and was the 1st registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

None of the 21 studies testing rimonabant in Obesity is open now. The open studies under Obesity, anywhere →

About rimonabant

Rimonabant: first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies testing rimonabant in Obesity as a file.
02

Study summary

To assess the effect on weight loss and weight maintenance over a period of one year when prescribed with a hypocaloric diet in obese patients with Type 2 Diabetes

03

Conditions studied

  • Obesity
  • Diabetes Mellitus, Non-Insulin-Dependent
  • Obesity in Diabetes

Keywords

  • Diabetes
  • Obesity
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  • must be greater than 27 and less than 40
  • Treated Type 2 Diabetes on single therapy treatment for at least 1 year
  • Stable weight (variation of less than 5 kg within 3 months prior to screening visit)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,045 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Change in body weight

Secondary outcomes

  1. Metabolic parameters

07

Study locations

55 sites
  • Innovative Clinical Trials
    Birmingham, Alabama 35209, United States
  • Lovelace Scientific Resources
    Phoenix, Arizona 85016, United States
  • Advanced Clinicla Therapeutics, LLC
    Tucson, Arizona 85712, United States
  • Southern California Prevention and Research Center Inc. (SPARC)
    Encino, California 91436, United States
  • Anderson Clinical Research
    San Bernardino, California 92408, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • North East Clinical Research
    Hamden, Connecticut 06518, United States
  • Clinical Research of South Florida
    Coral Gables, Florida 33134, United States
  • Jackson Downey, MD
    Jacksonville, Florida 32205, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32205, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • DMI Helathcare Group
    Largo, Florida 33773, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32806, United States
  • University Clinical Research
    Pembroke Pines, Florida 33024, United States
  • Comprehensive NeuroScience, Inc.
    Sarasota, Florida 34232, United States
  • Metabolic Research Institute
    West Palm Beach, Florida 33401, United States
  • CSRA Partners in Health, Inc.
    Augusta, Georgia 30909, United States
  • nTouch Research
    Marietta, Georgia 30066, United States
  • MediSphere Medical Research Center, LLC
    Evansville, Indiana 47714, United States
  • Physicians Research Group
    Indianapolis, Indiana 46250, United States
  • Kansas University Medical Center
    Kansas City, Kansas 66160, United States
  • Gulf States Clinical Trails, LLC
    Kenner, Louisiana 70062, United States
  • Medical Research Institute
    Slidell, Louisiana 70458, United States
  • Androscoggin Cardiology Associates
    Auburn, Maine, United States
  • Phase III Clinical Research
    Fall River, Massachusetts 02720, United States
  • JM Clinical Trials, Inc.
    Swansea, Massachusetts 02777, United States
  • Twin Cities Clinical Research
    Arden Hills, Minnesota 55126, United States
  • Lovelace Scientific Resources
    Las Vegas, Nevada 89014, United States
  • Endocrinology and Diabetes Consultants, PC
    Dover, New Hampshire 03820, United States
  • Radiant Reseach-Moorestown
    Moorestown, New Jersey 08057, United States
  • Lovelace Scientific Resources
    Albuquerque, New Mexico 87108, United States
  • Physician Clinical Research Service
    White Plains, New York 10605, United States
  • Center for Nutrition and Preventive Medicine
    Charlotte, North Carolina 28207, United States
  • Radiant Research
    Cincinnati, Ohio 45236, United States
  • MFP Research, Inc.
    Cincinnati, Ohio 45242, United States
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
  • Radiant Research
    Portland, Oregon 97201, United States
  • Medical University of South Carolina, Division of Clinical Pharmacology
    Charleston, South Carolina 29425, United States
  • Costal Carolina Research Center
    Mt. Pleasant, South Carolina 29464, United States
  • TriCities Medical Reseach
    Bristol, Tennessee 37620, United States
  • Diabetes $ Glandular Disease Clinic, PA
    San Antonio, Texas 78229-4810, United States
  • Endocrine and Diabetes
    Ogden, Utah 84403, United States
  • National Clinical Research
    Richmond, Virginia 23294, United States
  • Salem Veterans Affairs Medical Center (151)
    Salem, Virginia 24153, United States
  • The Chase Wellness Center, Inc.
    Virginia Beach, Virginia 23455, United States
  • Sanofi-aventis Administrative Office
    Buenos Aires, Argentina
  • Sanofi-aventis Administrative Office
    Diegem, Belgium
  • Sanofi-aventis Administrative Office
    Laval, Canada
  • Sanofi-aventis Administrative Office
    Praha, Czech Republic
  • Sanofi-aventis Administrative Office
    Helsinki, Finland
  • Sanofi-aventis Administrative Office
    Paris, France
  • Sanofi-aventis Administrative Office
    Berlin, Germany
  • Sanofi-aventis Administrative Office
    Gouda, Netherlands
  • Sanofi-aventis Administrative office
    Warszawa, Poland
  • Sanofi-aventis Administrative Office
    Guildford Surrey, United Kingdom
08

References and documents

Publications

  • Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF; RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet. 2006 Nov 11;368(9548):1660-72. doi: 10.1016/S0140-6736(06)69571-8. Erratum In: Lancet. 2006 Nov 11;368(9548):1650. PubMed 17098084 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2001, a primary completion of May 2004 and a completion of May 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2002
First posted
Jan 24, 2002
Start
Oct 2001
Primary completionActual
May 2004
CompletionActual
May 2004
Last update
Apr 20, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00029848
Lead sponsor
Sanofi
First posted
Jan 24, 2002
Start date
Oct 2001
Primary completion
May 2004
Completion
May 2004
Last update
Apr 20, 2009

Study contacts

ICD CSD
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rimonabant

Start the discussion